TAK 272

Drug Profile

TAK 272

Alternative Names: TAK-272

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Discontinued Hypertension

Most Recent Events

  • 13 Mar 2017 Takeda, the Innovation Network Corporation of Japan and MEDIPAL HOLDINGS CORPORATION agree to establish joint venture company SCOHIA PHARMA for development of eight of Takeda's products including TAK 272
  • 01 Aug 2016 Takeda completes a phase II trial in Diabetic nephropathies in Japan (NCT02332824)
  • 01 Jul 2016 Takeda completes a phase I trial in patients with renal or hepatic impairment in Japan (PO) (NCT02367872; JapicCTI-152790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top